SCHEMBL3973642

SCHEMBL3973642

CCOC(=O)c1occ(-c2cccc(O)c2)c1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.46
TP53 P04637 1/20 0.46
GAA P10253 5/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 7/20 0.44
HPGD P15428 6/20 0.44
KDM4E B2RXH2 4/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
LMNA P02545 3/20 0.44
NPC1 O15118 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 3/20 0.43
CCNB2 O95067 1/20 0.43
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNA2 P20248 1/20 0.43
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3981475 0.95 GAA (0.45) MAPTTP53GAAMEN1KMT2A
SCHEMBL3982596 0.84 PPARG (0.51) MAPTMEN1KMT2A
SCHEMBL3978466 0.82 PPARG (0.51) MAPTMEN1KMT2A
SCHEMBL3973638 0.82 FABP3 (0.43) MAPTGAAALDH1A1HPGDKDM4E
SCHEMBL4282758 0.81 CDC7 (0.48) MAPTGAAMEN1KMT2AALDH1A1
SCHEMBL3978078 0.81 ALDH1A1 (0.51) MAPTTP53GAAMEN1KMT2A
SCHEMBL3982581 0.80 PPARG (0.51) MAPTGAAMEN1KMT2A
SCHEMBL3977097 0.80 FNTA (0.46) MAPTTP53GAAMEN1KMT2A
SCHEMBL3982728 0.77 MAPT (0.41) MAPTGAAALDH1A1HPGDKDM4E
SCHEMBL3980972 0.77 FFAR1 (0.40) MAPTGAAALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100543022-C 2-furancarboxylic acid hydrazide compound and contain the pharmaceutical composition of this compound DAINIPPON PHARMACEUTICAL CO (JP) 2009-09-23 CN disclosed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
CN-1628111-A 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO (JP) 2005-06-15 CN disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 MAPT 4833/4885TP53 2395/4885GAA 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.